Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity

Leukemia volume 19, pages 1270–1272 (2005)Cite this article

TO THE EDITOR

A majority of acute myeloid leukemia (AML) patients in complete remission will eventually relapse due to persistence of minimal residual disease (MRD). Development of alternative therapeutic approaches to prevent relapse is a great challenge. Dendritic cell (DC)-based immunotherapy targeting residual leukemic cells might offer an interesting adjuvant therapy. Effective induction of antileukemia responses in vivo requires DCs with high expression levels of costimulatory molecules, capacity to migrate from the vaccination site to T-cell areas of secondary lymph nodes, and in addition, ability to secrete type-1 immunity cytokines. Previously, we demonstrated that in vitro treatment of AML cells with cytokines or calcium ionophores results in differentiation towards leukemic DC-like antigen presenting cells (AML-APCs) in approximately 75% of the patients. Moreover, these AML-APCs are able to induce autologous antileukemia T-cell responses in vitro. AML-APCs generated in calcium ionophore-based cultures are more mature with respect to expression of costimulatory molecules, CD83 and HLA-DR, and hence T-cell stimulatory capacity, than AML-APCs from cytokine-based cultures.1 However, little is known about the migratory capacity of leukemia-derived APCs in AML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Westers TM, Stam AG, Scheper RJ, Regelink JC, Nieuwint AW, Schuurhuis GJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003; 52: 17–27.

    Article  CAS  Google Scholar 

  2. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934–5937.

    Article  CAS  Google Scholar 

  3. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M . Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354–1361.

    Article  CAS  Google Scholar 

  4. Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol 2004; 173: 2855–2865.

    Article  CAS  Google Scholar 

  5. Camporeale A, Boni A, Iezzi G, Degl’Innocenti E, Grioni M, Mondino A et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003; 63: 3688–3694.

    CAS  PubMed  Google Scholar 

  6. Ishii K, Kurita-Taniguchi M, Aoki M, Kimura T, kashiwazaki Y, Matsumoto M et al. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy. Immunol Lett 2005; 98: 280–290.

    Article  CAS  Google Scholar 

  7. Mohty M, Isnardon D, Blaise D, Mozziconacci MJ, Lafage-Pochitaloff M, Briere F et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 2002; 16: 2267–2274.

    Article  CAS  Google Scholar 

  8. Eisendle K, Lang A, Eibl B, Nachbaur D, Glassl H, Fiegl M et al. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 2003; 120: 63–73.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

    T M Westers, I Houtenbos, N C L Snoijs, A A van de Loosdrecht & G J Ossenkoppele

Authors
  1. T M Westers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Houtenbos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N C L Snoijs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A A van de Loosdrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G J Ossenkoppele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T M Westers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Westers, T., Houtenbos, I., Snoijs, N. et al. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia 19, 1270–1272 (2005). https://doi.org/10.1038/sj.leu.2403794

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403794

This article is cited by

Search

Advanced search

Quick links